Small Pharma Reports Fiscal Second Quarter 2023 Highlights
Last patient dosed in Phase IIa trial for lead product candidate, SPL026 with supportive therapy for the treatment of Major...
Clinical Trial
NeuBase Therapeutics Announces Strategic Restructuring Focused on Advancing Its Platform in Gene Editing
Workforce reductions of ~60% and implementation of a robust cost reduction plan are expected to extend the Company’s cash runway...
BMF-219 Enters the Clinic for KRAS Solid Tumors
Biomea Fusion announces FDA clearance of Investigational New Drug (IND) application for covalent menin inhibitor BMF-219 in KRAS solid tumors.Biomea...
Salarius Pharmaceuticals Announces 1-for-25 Reverse Stock Split
HOUSTON, Oct. 14, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company developing medicines for patients...
Biofrontera Inc. Adopts Limited Duration Shareholder Rights Plan
WOBURN, Mass., Oct. 14, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (the “Company”), a biopharmaceutical company specializing in the...
Novan and EPI Health, a Novan Company, Announce Abstracts Accepted for Poster Presentation at the 42nd Annual Fall Clinical Dermatology Conference®
DURHAM, N.C., Oct. 14, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN) and EPI Health, a...
Aligos Therapeutics Initiates Dosing In Healthy Volunteers With siRNA Drug Candidate ALG-125755
Single ascending doses to be evaluated in healthy volunteers in Q4 2022 Single ascending doses to be evaluated in subjects...
BridgeBio Pharma Presents 12-month Results from Phase 2 Study of BBP-418 in Limb-Girdle Muscular Dystrophy Type 2i (LGMD2i)
Novel assay developed to assess the extent of alpha-dystroglycan (⍺DG) glycosylation, the core pathology of LDMD2i, from muscle biopsy samplesIncrease...
Novartis receives positive CHMP opinion for Pluvicto® for patients with progressive, PSMA-positive metastatic castration-resistant prostate cancer
Phase III VISION trial showed Pluvicto® plus best standard of care significantly improved survival for patients with pre-treated PSMA-positive mCRPC1Approximately...
Algernon Pharmaceuticals Announces Dr. Rick Strassman author of “DMT: The Spirit Molecule” to Join CEO Christopher J. Moreau for Keynote Science Address at Wonderland Conference
VANCOUVER, British Columbia, Oct. 14, 2022 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB:...
Myovant Sciences to Host Second Fiscal Quarter 2022 Earnings Conference Call at 5:00 p.m.
BASEL, Switzerland, Oct. 14, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), today announced it will host a webcast and conference...
Verona Pharma Announces Analyses Demonstrating Ensifentrine Reduced Exacerbation Rates Across Subgroups in Phase 3 ENHANCE-2 Trial for COPD
LONDON and RALEIGH, N.C., Oct. 14, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”),...
Enliven Therapeutics and Imara Announce Merger Agreement
Merger to create Nasdaq-listed, clinical-stage biopharmaceutical company focused on advancing Enliven’s portfolio of precision oncology programsCombined company is expected to...
Kymera Therapeutics to Hold Investor Webcast on December 14 to Share Clinical Data from KT-474 Phase I Patient Cohort and Oncology Pipeline
Dosing in KT-474 Phase 1 HS and AD patient cohort (Part C) complete KT-413 and KT-333 continuing in Phase 1...
Travere Therapeutics Provides Regulatory Update on its Sparsentan Program for IgA Nephropathy
Conference call and webcast to be held at 4:30p.m. ET SAN DIEGO, Oct. 13, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics,...
IO Biotech Announces Appointment of New Chief Financial Officer
NEW YORK, Oct. 13, 2022 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer...
Invivyd Appoints Fred Driscoll as Interim Chief Financial Officer and Announces Resource Reallocation to Maximize Integrated Discovery Platform
WALTHAM, Mass., Oct. 13, 2022 (GLOBE NEWSWIRE) -- Invivyd, (Nasdaq: IVVD) a clinical-stage biopharmaceutical company on a mission to protect...
BridgeBio Pharma Presents Updated Positive Data from its BBP-812 Canavan Disease Gene Therapy Program at the 51st Annual Meeting of the Child Neurology Society
- Robust post-dosing changes continue to be seen in key markers associated with severity of disease - Pharmacodynamic data from...
PepGen Presents Data from its Duchenne Muscular Dystrophy Program at World Muscle Society Congress
BOSTON, Oct. 13, 2022 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of...
CORRECTION — SOLVE FSHD invests US$10 Million in Vita Therapeutics
VANCOUVER, British Columbia, Oct. 13, 2022 (GLOBE NEWSWIRE) -- In a release issued today by SOLVE FSHD under the same headline,...